Blog

DEEP RESEARCH · MEDPACTO

Medpacto IR Update (2025-11-25): Vactosertib, MP010, MP2021 Pipeline Check

A pipeline check of Medpacto's three lead assets — Vactosertib, MP010, MP2021 — based on the November 2025 IR deck.

Published: 2025-11-25 · IR follow-up note · Original Naver Blog post · IR PDF download

You are responsible for your own investment decisions. This material is research and is not a buy or sell recommendation.

0. Bottom Line First

Three takeaways from Medpacto's November 2025 IR: (1) The most-advanced asset, Vactosertib, shows 2–3x differentiation versus standard of care across indications (osteosarcoma ORR 36.4%, NSCLC mOS 41.9 months). (2) Next-gen assets MP010 (targeted TGF-β trap) and MP2021 (first-in-class TM4SF19 target) aim for 2026 IND filings. (3) The near-term trigger is hitting the KRW 3 bn annual revenue threshold and a global out-licensing deal.

  • Vactosertib: Differentiated data across osteosarcoma, NSCLC, and MSS-mCRC. U.S. FDA granted ODD, RPDD, and Fast Track.
  • MP010: A "GPS-equipped" TGF-β trap that binds EDB-FN expressed on tumor tissue. >70% CR with monotherapy in a pancreatic cancer model.
  • MP2021: Targets TM4SF19, a protein first identified by Medpacto. Potential across osteoporosis, arthritis, even obesity.
  • Near-term check: Hitting KRW 3 bn full-year revenue (KRW 2.47 bn already booked through Q3 — highly likely) removes the watch-list risk.

1. Vactosertib — TGF-β1 Inhibitor

The most clinically advanced asset and the pillar of corporate value.

1.1 Edge vs. Competing Drugs

Osteosarcoma

ORR 36.4%

~3x the 8–13% ORR of off-label standards (Regorafenib, Sorafenib). 1 complete response in a refractory/relapsed monotherapy trial. There is no approved second-line standard of care today.

NSCLC

mOS 41.9 months

Versus 11.2 months for Imfinzi monotherapy. The Imfinzi + Vactosertib combo extended median OS by ~3.7x (30+ months).

MSS-mCRC

mOS 17.4 months

Versus 6.4 months for regorafenib. The Keytruda combo more than doubled median OS.

Regulatory

FDA Triple Designation

Orphan Drug (ODD), Rare Pediatric Disease (RPDD), and Fast Track — speeds development and unlocks the Priority Review Voucher (PRV) opportunity.

1.2 Milestones to Watch

  • Osteosarcoma Phase 2 data + accelerated approval optionality: Given the rare-disease setting, Phase 2 results alone could support an accelerated approval filing.
  • Global Phase 2b/3 partnership for CRC: Late-stage trials are expensive; co-development or out-licensing (L/O) is the key share-price catalyst.

2. MP010 — Next-Gen Immuno-Oncology (TME-DP)

The successor to Vactosertib. Recently selected for a KDDF national R&D program.

2.1 Core Edge — A "GPS-Equipped" Targeted TGF-β Trap

Official fact: Existing systemic TGF-β traps act body-wide and carry toxicity issues (skin toxicity, bleeding) or low tumor delivery.

Interpretation: MP010 binds EDB-FN, which is over-expressed only on tumor tissue. The drug acts "like a GPS" — it travels to and stays at the tumor, where it suppresses TGF-β. The deck shows drug retention inside the tumor 9 days post-dose, improving both intratumoral concentration and residence time.

Complete response & immune memory: Monotherapy produced >70% CR in a refractory pancreatic cancer model. After tumor clearance, re-challenge with cancer cells did not regrow tumors — evidence of long-term Memory T-cell formation. This suggests recurrence prevention potential.

2.2 Milestones

  • 2026 IND filing: Targets Phase 1 IND submission after completing GLP toxicology and other preclinical work.
  • KDDF program output: Funded for 2 years; resulting toxicity/efficacy data become the basis for future out-licensing.

3. MP2021 — Bone Disease & Anti-Aging

Expands the pipeline beyond oncology into aging and metabolic disease.

3.1 Core Edge — First-in-Class Novel Target

Official fact: MP2021 targets TM4SF19, a protein first identified by Medpacto. It suppresses osteoclast multi-nucleation (the bone-resorbing cells), fundamentally preventing bone loss while also suppressing inflammation — a dual effect.

Interpretation: Existing osteoporosis or arthritis drugs are limited to symptom relief or a single mechanism, with side-effect issues. If the TM4SF19 hypothesis holds in the clinic, the asset could become a platform rather than a single-indication drug.

3.2 Obesity Optionality

In a high-fat-diet obesity model, MP2021 suppressed adipocyte differentiation and reduced inflammation, leading to weight reduction — extending optionality into the currently hot obesity drug market.

3.3 Milestones

  • 2026 IND filing: Like MP010, targeting Phase 1 entry in 2026.
  • Indication expansion data: Watch for additional preclinical readouts in rheumatoid arthritis, obesity, etc.

4. Key Points for Investors

2025–2027 Medpacto Milestone MapShort-term financial cleanup → mid-term out-licensing → long-term next-gen entry
Next 6 moReach KRW 3 bn revenue (Q3 YTD: 2.47 bn) → clear watch-list risk
6–12 moOsteosarcoma Phase 2 progress · PRV value highlighted
1–2 yrGlobal big-pharma L/O on NSCLC/CRC data
2026MP010 & MP2021 IND filings
A signed L/O is the main share-price catalyst; new INDs validate pipeline diversification.

Short Term (6–12 months)

  • Financial health: Confirm KRW 3 bn annual revenue (KRW 2.47 bn through Q3 — highly likely) — fully clears the watch-list risk.
  • Osteosarcoma clinical: Watch how fast Phase 2 progresses under ODD benefits and whether the PRV value becomes a recognized lever.

Mid–Long Term (1–2 years)

  • Out-licensing (L/O): A meaningful deal with a global big pharma on the NSCLC (41.9-month OS) and CRC data is the key share-price catalyst.
  • New clinical entries: Whether the planned 2026 Phase 1 entries for MP010 and MP2021 happen on schedule.

Sources

Naver original